The Iowa Court of Appeals has affirmed summary judgment entered in favor of both branded and generic manufacturers of metoclopramide, looking at Mensing’s effect on both in the process. In Huck v. Trimark Physicians Group, 2013 Iowa App. LEXIS 435 (April 24, 2013), the Plaintiff sued manufacturers of brand-name and generic metoclopramide after she developed tardive dyskinesia while taking the drug. While her doctor relied upon the branded product’s labeling as published in the Physician’s Desk Reference –which warned about the risk of tardive dyskinesia - the Plaintiff took only the generic form of the drug. Id. at *2. Plaintiff relied on the fact that after she had taken the drug for about five months, the FDA approved a label change for the branded product to include a warning that the drug should not be used for more than 12 weeks; the branded product’s label was updated accordingly, but the generic’s was not. Id. at *3-4.